The tirzepatide starting dose: what it is, why it matters, and what comes next

Step 1, The 2.5 mg opening phase: settling in, not treating yet

There is a misconception that comes up often: people starting tirzepatide at 2.5 mg sometimes worry it is not working because they feel little change in appetite. That is entirely expected. The 2.5 mg dose is not designed to produce significant weight loss on its own; its job is to introduce the medicine to your system gently, reducing the chance of nausea and other gastrointestinal discomfort in the early weeks. Think of it as the body's calibration period.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, it acts on two gut-hormone pathways involved in appetite signalling and the rate at which your stomach empties. If you want a fuller picture of what starting Mounjaro at 2.5 mg involves and why that figure is where treatment begins, there is dedicated guidance covering exactly that. The NHS medicines page for tirzepatide describes this graduated schedule clearly, and the full prescribing detail sits in the Summary of Product Characteristics on the eMC. Your prescriber works from both.

The practical upshot: if you are at 2.5 mg and wondering whether anything is happening, you are at the right stage of the process. Appetite changes typically become more noticeable once the dose increases. Patience here is not weakness; it is the design of the treatment.

Step 2, Moving through the dose ladder: what the four-week intervals mean

After four weeks at 2.5 mg, the standard schedule moves to 5 mg. From there, each four-week interval offers the option to step up by 2.5 mg increments, through 7.5, 10, 12.5 and potentially to the 15 mg maximum. The word "option" matters: titration is guided by your prescriber's assessment of how well you are tolerating the current dose, not by a mechanical clock. If side effects at a given level have not settled, staying at that dose for longer is a clinical decision, not a failure.

People sometimes ask whether there is any benefit in starting higher to accelerate results, and if you are weighing that up, our guide to what counts as a good starting dose for tirzepatide walks through the clinical reasoning behind the opening figure. The evidence base, including the SURMOUNT-1 trial published in the New England Journal of Medicine, was built on this graduated approach, the substantial average weight reductions seen at 15 mg over 72 weeks reflect a carefully managed titration, not a rapid dose-load. Skipping steps is not part of the licensed schedule.

If you are curious about what starting at 5 mg looks like in specific clinical circumstances, there is a dedicated page covering that scenario. For most people beginning treatment, though, 2.5 mg is the right and only starting point.

Step 3 (Responding to side effects during titration

Gastrointestinal effects) nausea, loose stools, constipation, reflux, a reduced appetite that sometimes tips into feeling off food entirely, are the most commonly reported experiences in the early dose phases. They tend to be most prominent in the first one to two weeks after a dose increase, then ease as the body adapts. Staying well hydrated and eating smaller portions can help; your prescriber and the Patient Information Leaflet that comes with your pen are the right resources for personalised guidance.

Serious side effects are uncommon, but there are a few that warrant prompt medical attention: severe, persistent abdominal pain that radiates toward the back (which could indicate pancreatitis), signs of a significant allergic reaction, or symptoms of gallbladder problems. The MHRA's Yellow Card scheme exists so that patients can report unexpected reactions directly, a genuinely useful safety feedback loop, not just a formality. Tirzepatide carries the Black Triangle (▼) designation in the UK, meaning it is subject to additional post-marketing surveillance, which is standard for newer medicines.

If you want to think through the cost side of treatment while you are reading about the clinical picture, our guide to Mounjaro pricing in the UK sets out what private treatment typically involves and what to look for when comparing services.

Step 4, The prescriber's role at every stage, not just at the start

One thing that distinguishes a well-run tirzepatide service from a form-filling exercise is what happens after week one. The starting dose of tirzepatide is relatively straightforward to describe; managing the full titration schedule, assessing whether a dose increase is appropriate, and reviewing whether treatment should continue, those are ongoing clinical decisions, not administrative ones.

At nume, a GPhC-registered Independent Prescriber personally reviews your case before every stage of treatment. There is no automated approval pathway. If you are thinking about how the Mounjaro starting dose is determined and what your prescriber is weighing up at that first decision point, that question has its own detailed answer. For a broader grounding in tirzepatide as a treatment, the Mounjaro overview page covers eligibility, the mechanism, and the clinical evidence in full.

If you would like to explore whether tirzepatide is right for you, our prescribers are available seven days a week. Speak to our prescribers through a free consultation, no waiting list, reviewed the same day your submission arrives.